Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion
Portfolio Pulse from
Intellia Therapeutics (NTLA) is facing a class action lawsuit alleging false and misleading statements about its drug development program, particularly regarding NTLA-3001. The lawsuit claims the company misrepresented the viability and potential of its viral-based editing drug. On January 9, 2025, Intellia announced a reorganization and discontinued NTLA-3001, causing the stock to drop over 15%.
April 11, 2025 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The lawsuit alleges Intellia misrepresented its drug development capabilities, potentially damaging investor confidence and the company's reputation in the genome editing space.
The class action lawsuit directly targets Intellia, alleging systematic misrepresentation of its drug development program. The stock already experienced a 15% drop, and potential legal consequences could further impact investor sentiment and stock performance.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100